Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GI-6207 in Recurrent Medullary Thyroid Cancer
NCT01856920Phase 2Completed
- Sponsor
- ImmunityBio, Inc.
- Start
- Mar 2013
- Primary completion
- May 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of GI-6207 in Medullary Thyroid Cancer (MTC), sponsored by ImmunityBio, Inc.. Started Mar 2013; status: completed.
02
Drugs
GI-6207
03
Conditions
Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on NCT01856920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01856920.